Gene Techno Science
Gene Techno Science (Kidswell Bio) is a Japanese biopharmaceutical company developing biosimilars (anti-VEGF antibodies for ophthalmology) and regenerative cell therapies, including deciduous tooth stem cell treatments for chronic cerebral palsy.
- Company typePublic
- Founded2001
- HeadquartersTokyo, Japan
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Gene Techno Science does
Gene Techno Science Co., Ltd. (operating as Kidswell Bio Corporation) is a Japanese biopharmaceutical company headquartered in Tokyo and listed on the Tokyo Stock Exchange (tyo:4584). Founded in 2001, the company operates two core business segments: a Biosimilar Business developing cost-effective biosimilar versions of established biologics — including an anti-VEGF antibody biosimilar for ophthalmic conditions — and a Cell Therapy Business focused on regenerative medicine applications, most notably clinical-stage use of deciduous tooth stem cells for chronic cerebral palsy treatment in partnership with Nagoya University.
The company generates revenue through commercialization and development of biosimilars and pipeline cell therapy candidates, distributing through established Japanese pharmaceutical wholesale channels. In FY2025 (ending March 2026), the company reported a 29.7% year-over-year increase in net sales but continued to post an operating loss; management has stated that biosimilar active pharmaceutical ingredient (API) price revisions are expected to drive profitability in FY2026. The company's stated strategic vision is 'KIDS WELL, ALL WELL,' positioning itself as a drug discovery venture focused on pediatric and family healthcare applications and aiming to commercialize Japanese biotechnology globally.
With 11-50 employees, Gene Techno Science maintains a lean operating profile relative to its dual R&D and commercialization mandate. Historically, the company raised approximately $30 million across multiple funding rounds between 2004 and 2013, including a $13.2 million round led by Whiz Partners. In April 2019, the company acquired Advanced Cell Technology and Engineering, expanding its regenerative medicine capabilities. The company communicates with investors primarily through IR disclosures, securities filings, and media coverage in Japanese biotech publications such as Nikkei Biotechnology and Chemical Industry Daily.
Gene Techno Science firmographics
Firmographics- Name
- Gene Techno Science
- Legal name
- Gene Techno Science Co., Ltd.
- Website
- https://g-gts.com
- Company type
- Public
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Gene Techno Science (Kidswell Bio) is a Japanese biopharmaceutical company developing biosimilars (anti-VEGF antibodies for ophthalmology) and regenerative cell therapies, including deciduous tooth stem cell treatments for chronic cerebral palsy.
- Ownership category
- akta.pro rank
Gene Techno Science industry classification
Industry- Product category
- Biopharmaceuticals (Biosimilars and Regenerative Medicine)
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Anti-VEGF Biosimilars (HLAIAFAG)
- akta.pro secondary industries
- Monoclonal Antibody (mAb) Biosimilars (HLAIAFAA), Cell Therapy Developers (Autologous) (HLAAABAA), Ophthalmology Specialty Pharmaceuticals (HLAIACAK), Biosimilar Commercialization & Market Access (pricing, tendering, interchangeability, distribution) (HLAAAHAL)
Keywords
Where Gene Techno Science is headquartered
LocationHeadquarters
- HQ city
- Tokyo
- HQ country
- Japan
- HQ region
- Asia
Markets served
Gene Techno Science business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Distribution channels1 record
Marketing channels3 records
Gene Techno Science product offering
Product offeringCore offering
Gene Techno Science researches, develops, and commercializes biopharmaceutical products through two business segments. The Biosimilar Business develops cost-effective biosimilar versions of established biologics, including an anti-VEGF antibody biosimilar targeting ophthalmic conditions. The Cell Therapy Business develops regenerative medicine treatments, including a stem cell therapy derived from deciduous (baby) teeth that is being evaluated in clinical trials for chronic cerebral palsy. Both segments are supported by an internal pipeline of biosimilar and cell therapy candidates at various stages of clinical development.
Product overview
Gene Techno Science (Kidswell Bio Corporation) operates as a biopharmaceutical company with two core business segments: a Biosimilar Business developing cost-effective biosimilar versions of established biologics, and a Cell Therapy Business focused on regenerative medicine applications including stem cell-based treatments. The company is pursuing drug development through its pipeline platform to address unmet medical needs in ophthalmology and other therapeutic areas.
Differentiator
Problem solved
Functional benefit
Products and services
- Biosimilar Business (バイオシミラー事業) Development and commercialization of biosimilar pharmaceutical products, including anti-VEGF antibody biosimilars aimed at ophthalmic conditions, marketed through pharmaceutical wholesale channels in Japan.
- Cell Therapy Business (細胞治療事業／再生医療) Regenerative medicine-focused cell therapy business, including clinical-stage development of stem cell-based treatments such as deciduous tooth stem cell therapy for chronic cerebral palsy, pursued in collaboration with academic medical centers.
- Drug Development Pipeline Internal pipeline platform spanning biosimilar and cell therapy candidates at multiple stages of clinical development, intended to feed both the Biosimilar Business and the Cell Therapy Business with future commercial and clinical assets.
Companies that use Gene Techno Science
Customer profileSegments1 record
Ideal customer profiles2 records
Gene Techno Science technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Gene Techno Science partnerships and signals
Strategic signalScale indicators2 records
Recent moves5 records
Expansion highlights3 records
Gene Techno Science competitors and assessment
Company assessmentMarket position
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Gene Techno Science social profiles
Digital presenceGene Techno Science financial estimates
Financial estimateRevenue estimate
Valuation estimate
Gene Techno Science leadership team
Management profileNumber of profiles
Profiles1 record
Gene Techno Science funding detail
Funding detailFunding overview
Funding rounds5 records
Investors18 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Gene Techno Science M&A and investment
M&A and investmentM&A1 record
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Gene Techno Science
What does Gene Techno Science do?
Gene Techno Science researches, develops, and commercializes biopharmaceutical products through two business segments. The Biosimilar Business develops cost-effective biosimilar versions of established biologics, including an anti-VEGF antibody biosimilar targeting ophthalmic conditions. The Cell Therapy Business develops regenerative medicine treatments, including a stem cell therapy derived from deciduous (baby) teeth that is being evaluated in clinical trials for chronic cerebral palsy. Both segments are supported by an internal pipeline of biosimilar and cell therapy candidates at various stages of clinical development.
Is Gene Techno Science a public or private company?
Gene Techno Science is a public company. It is classified as public and is currently operating.
When was Gene Techno Science founded?
Gene Techno Science was founded in 2001. It employs 11 to 50 people.
Where is Gene Techno Science based?
Gene Techno Science is headquartered in Tokyo, Japan, in the Asia region.
Does Gene Techno Science have an API?
No public API is recorded for Gene Techno Science.
What industry is Gene Techno Science in?
Gene Techno Science's product category is Biopharmaceuticals (Biosimilars and Regenerative Medicine). Its primary akta.pro industry code is HLAIAFAG, Anti-VEGF Biosimilars, with a secondary code of HLAIAFAA, Monoclonal Antibody (mAb) Biosimilars. Its NAICS code is 325414 and its SIC code is 2836.